Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Butyrolactone I

CDK inhibitor
 
BML-CC210-0200 200 µg 110.00 USD
 
BML-CC210-1000 1 mg 457.00 USD
Do you need bulk/larger quantities?
 
Replaces Prod. #: ALX-350-250

Cell permeable and selective inhibitor of the cyclin-dependent kinases CDK1/cyclin B, CDK2 and CDK5. Inhibits cell cycle progression at the G1/S and G2/M transitions. G1/S and G2/M transitions, in W138 cells, were inhibited, concurrent with inhibition of the phosphorylations of, respectively, retinoblastoma protein and histone H1. It is an important tool for probing the cellular roles of CDKs. Blocks Fas-induced apoptosis. Displays antitumor activity.

Product Specification

Formula:C24H24O7
 
MW:424.5
 
CAS:87414-49-1
 
Purity:≥99% (TLC)
 
Appearance:White solid.
 
Solubility:Soluble in 100% ethanol (25mg/ml) or DMSO(>10mg/ml).
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Use/Stability:Stable for at least 1 year after receipt when stored, as supplied, at -20°C. Stock solutions are stable for up to 3 months at -20°C.
 
Handling:Protect from light.
 
ALX-350-250
Please mouse over
ALX-350-250

Product Literature References

Induction of secondary metabolism of Aspergillus terreus ATCC 20542 in the batch bioreactor cultures: T. Boruta, et al.; Appl. Microbiol. Biotechnol. 100, 3009 (2016), Application(s): Cell culture, Abstract; Full Text
Regulation of mitotic function of Chk1 through phosphorylation at novel sites by cyclin-dependent kinase 1 (Cdk1): T. Shiromizu, et al.; Genes Cells 11, 477 (2006), Abstract;
Involvement of Cdk5/p25 in digoxin-triggered prostate cancer cell apoptosis: H. Lin, et al.; J. Biol. Chem. 279, 29302 (2004), Abstract; Full Text
Butyrolactone I reversibly inhibits meiotic maturation of bovine oocytes, without influencing chromosome condensation activity: M. Kubelka, et al.; Biol. Reprod. 62, 292 (2000), Abstract; Full Text
Butyrolactone I induces cyclin B1 and causes G2/M arrest and skipping of mitosis in human prostate cell lines: M. Suzuki, et al.; Cancer Lett. 138, 121 (1999), Abstract;
Effects of cyclin-dependent kinase inhibitors on transcription and ocular circadian rhythm of Aplysia: N. Sankrithi and A. Eskin; J. Neurochem. 72, 605 (1999), Abstract;
An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells: M. Wada, et al.; Anticancer Res. 18, 2559 (1998), Abstract;
Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines: K. Nishio, et al.; Anticancer Res. 16, 3387 (1996), Abstract;
Transcriptional activation of the cdc2 gene is associated with Fas- induced apoptosis of human hematopoietic cells: Y. Furukawa, et al.; J. Biol. Chem. 271, 28469 (1996), Abstract; Full Text
Evidence for cdk5 as a major activity phosphorylating tau protein in porcine brain extract: T. Hosoi, et al.; J. Biochem. 117, 741 (1995), Abstract;
A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression: M. Kitagawa, et al.; Oncogene 9, 2549 (1994), Abstract;
Inhibition of cell cycle oscillation of DNA replication by a selective inhibitor of the cdc2 kinase family, butyrolactone I, in Xenopus egg extracts: A. Someya, et al.; BBRC 198, 536 (1994), Abstract;
Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase: M. Kitagawa, et al.; Oncogene 8, 2425 (1993), Abstract;

Related Literature

Product Flyers
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,